Brokerages predict that Rocket Pharmaceuticals Inc (NASDAQ:RCKT) will announce earnings of ($0.52) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Rocket Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.69) and the highest estimate coming in at ($0.40). Rocket Pharmaceuticals posted earnings per share of ($0.66) in the same quarter last year, which would indicate a positive year-over-year growth rate of 21.2%. The company is expected to issue its next earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Rocket Pharmaceuticals will report full year earnings of ($1.68) per share for the current financial year, with EPS estimates ranging from ($1.89) to ($1.54). For the next financial year, analysts anticipate that the company will report earnings of ($2.28) per share, with EPS estimates ranging from ($3.45) to ($1.57). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Rocket Pharmaceuticals.
Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.11.
A number of equities research analysts have recently commented on the company. Zacks Investment Research downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. William Blair reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 10th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Rocket Pharmaceuticals in a research note on Friday. Robert W. Baird lifted their price target on Rocket Pharmaceuticals from $30.00 to $41.00 and gave the company an “outperform” rating in a report on Friday. Finally, Cowen reaffirmed a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Sunday, November 17th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $31.50.
Rocket Pharmaceuticals stock traded up $2.65 on Friday, hitting $22.37. The company’s stock had a trading volume of 1,002,018 shares, compared to its average volume of 242,551. Rocket Pharmaceuticals has a one year low of $10.75 and a one year high of $24.42. The firm has a market cap of $992.91 million, a P/E ratio of -11.83 and a beta of 2.78. The company has a quick ratio of 11.07, a current ratio of 11.07 and a debt-to-equity ratio of 0.20. The company has a fifty day moving average price of $15.56 and a 200-day moving average price of $13.98.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC raised its stake in shares of Rocket Pharmaceuticals by 200.0% in the 3rd quarter. Lindbrook Capital LLC now owns 3,000 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 2,000 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Rocket Pharmaceuticals by 41.5% during the third quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 8,150 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 2,390 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Rocket Pharmaceuticals by 41.7% during the second quarter. JPMorgan Chase & Co. now owns 8,168 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 2,404 shares in the last quarter. Bank of Montreal Can acquired a new stake in Rocket Pharmaceuticals in the second quarter worth approximately $38,000. Finally, Northern Trust Corp lifted its position in Rocket Pharmaceuticals by 0.9% in the second quarter. Northern Trust Corp now owns 308,274 shares of the biotechnology company’s stock worth $4,624,000 after purchasing an additional 2,784 shares during the period. Institutional investors own 93.86% of the company’s stock.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.